Search results for " relap"

showing 10 items of 130 documents

Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MS.

2019

ObjectiveWe explored the incremental value of adding multiple disease activity biomarkers in CSF and serum for distinguishing MRI-based benign from aggressive MS in early disease course.MethodsNinety-three patients diagnosed with clinically isolated syndrome (CIS) or early MS were divided into 3 nonoverlapping severity groups defined by objective MRI criteria. Ninety-seven patients with noninflammatory neurologic disorders and 48 patients with other inflammatory neurologic diseases served as controls. Leukocyte subsets in the CSF were analyzed by flow cytometry. CSF neurofilament light chain (NfL) and chitinase-3-like protein 1 (CHI3L1) levels were measured by ELISA. Serum NfL levels were e…

0301 basic medicineAdultMalePathologymedicine.medical_specialtyAdolescent41medicine.medical_treatmentCHI3L1ArticleFlow cytometryCohort Studies03 medical and health sciencesYoung Adult0302 clinical medicineText miningMultiple Sclerosis Relapsing-RemittingNeurofilament ProteinsMedicineHumansB cellAgedCD20Aged 80 and overB-LymphocytesClinically isolated syndromebiologymedicine.diagnostic_testbusiness.industryMultiple sclerosisImmunotherapyMiddle Agedmedicine.diseaseMagnetic Resonance ImagingAxons030104 developmental biologymedicine.anatomical_structureCross-Sectional StudiesNeurologybiology.proteinDisease ProgressionFemaleNeurology (clinical)business030217 neurology & neurosurgeryDemyelinating DiseasesNeurology(R) neuroimmunologyneuroinflammation
researchProduct

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.

2021

ObjectiveTo evaluate the clinical consequences of extended interval dosing (EID) of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) during the coronavirus disease 2019 (COVID-19) pandemic.MethodsIn our retrospective, multicenter cohort study, we compared patients with RRMS on EID (defined as ≥4-week delay of dose interval) with a control group on standard interval dosing (SID) at the same period (January to December 2020).ResultsThree hundred eighteen patients with RRMS were longitudinally evaluated in 5 German centers. One hundred sixteen patients received ocrelizumab on EID (median delay [interquartile range 8.68 [5.09–13.07] weeks). Three months after the last ocrelizumab in…

0301 basic medicineAdultMalemedicine.medical_specialty41Antigens CD19MedizinLogistic regressionAntibodies Monoclonal HumanizedArticle2303 medical and health sciencesDisability Evaluation0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInterquartile rangeInternal medicinemedicineHumansDosingLymphocyte CountPandemicsRetrospective Studies360B-Lymphocytes120business.industryMultiple sclerosisCOVID-19Retrospective cohort studyMiddle Agedmedicine.diseaseMagnetic Resonance Imaging030104 developmental biologyTreatment OutcomeNeurologyCohortOcrelizumabFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugCohort studyNeurology(R) neuroimmunologyneuroinflammation
researchProduct

Clinical implications of serum neurofilament in newly diagnosed MS patients: a longitudinal multicentre cohort study

2020

Abstract Background We aim to evaluate serum neurofilament light chain (sNfL), indicating neuroaxonal damage, as a biomarker at diagnosis in a large cohort of early multiple sclerosis (MS) patients. Methods In a multicentre prospective longitudinal observational cohort, patients with newly diagnosed relapsing-remitting MS (RRMS) or clinically isolated syndrome (CIS) were recruited between August 2010 and November 2015 in 22 centers. Clinical parameters, MRI, and sNfL levels (measured by single molecule array) were assessed at baseline and up to four-year follow-up. Findings Of 814 patients, 54.7% (445) were diagnosed with RRMS and 45.3% (369) with CIS when applying 2010 McDonald criteria (R…

0301 basic medicineAdultMalemedicine.medical_specialtyResearch paperClinical Decision-MakingIntermediate Filamentslcsh:Medicine610 Medicine & healthNewly diagnosedGeneral Biochemistry Genetics and Molecular BiologyMultiple sclerosis03 medical and health sciences0302 clinical medicineAtrophyMultiple Sclerosis Relapsing-RemittingNeurofilament ProteinsInternal medicineGermanymedicineHumansLongitudinal StudiesProspective Studiesddc:610610 Medicine & healthNeurofilament light chainlcsh:R5-920Clinically isolated syndromebusiness.industryMultiple sclerosislcsh:RMcDonald criteriaGeneral MedicineBiomarkermedicine.diseasesNfL030104 developmental biology030220 oncology & carcinogenesisCohortDisease ProgressionCommentaryBiomarker (medicine)Femalelcsh:Medicine (General)businessPredictionFunction and Dysfunction of the Nervous SystemBiomarkersCohort study
researchProduct

Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer

2018

Solid malignancies have been speculated to depend on cancer stem cells (CSCs) for expansion and relapse after therapy. Here we report on quantitative analyses of lineage tracing data from primary colon cancer xenograft tissue to assess CSC functionality in a human solid malignancy. The temporally obtained clone size distribution data support a model in which stem cell function in established cancers is not intrinsically, but is entirely spatiotemporally orchestrated. Functional stem cells that drive tumour expansion predominantly reside at the tumour edge, close to cancer-associated fibroblasts. Hence, stem cell properties change in time depending on the cell location. Furthermore, although…

0301 basic medicineColorectal cancerCellClone (cell biology)Mice NudeContext (language use)Colon cancer cancer stem cells tumor microenvironment.Article03 medical and health sciencesCancer stem cellCancer Stem CellsAntineoplastic Combined Chemotherapy ProtocolsmedicineTumor MicroenvironmentAnimalsHumansOsteopontin (OPN Spp1)OsteopontinStem Cell DynamicsCells CulturedCell ProliferationbiologyColon CancerGene Expression ProfilingCancerDisease RelapseTumour growthCell Biologymedicine.diseaseXenograft Model Antitumor AssaysCell biologyGene Expression Regulation NeoplasticOxaliplatinTamoxifen030104 developmental biologymedicine.anatomical_structureColonic Neoplasmsbiology.proteinNeoplastic Stem CellsTherapyStem cellCuesNature cell biology
researchProduct

The two faces of tumor-associated macrophages and their clinical significance in colorectal cancer

2019

© 2019 Pinto, Rios, Durães, Ribeiro, Machado, Mantovani, Barbosa, Carneiro and Oliveira. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

0301 basic medicineMaleColorectal cancerprognostic and tumor relapseMacrophages / immunologyhuman macrophage surface markers0302 clinical medicineTumor MicroenvironmentImmunology and AllergyColorectal Neoplasms / mortalityOriginal ResearchAged 80 and overTumor immunomodulationCD68tumor-associated macrophagesTumor-associated macrophagesTumor Microenvironment / immunologyMiddle AgedPrognosis3. Good healthMacrophage polarizationImmunohistochemistryFemaleHuman macrophage surface markerstumor immunomodulationColorectal NeoplasmsInfiltration (medical)lcsh:Immunologic diseases. AllergyAdultmacrophage polarizationImmunologyMacrophage polarizationcolorectal cancerBiologyPrognostic and tumor relapseColorectal Neoplasms / pathology03 medical and health sciencesYoung AdultImmune systemmedicineHumansAgedMacrophagesColorectal Neoplasms / immunologymedicine.diseaseColorectal cancer030104 developmental biologyCancer researchlcsh:RC581-607CD163CD80030215 immunology
researchProduct

The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis

2018

ObjectiveTo evaluate whether the clinical benefit and relapse rates in anti-muscle-specific kinase (MuSK) myasthenia gravis (MG) differ depending on the protocol of rituximab followed. MethodsThis retrospective multicentre study in patients with MuSK MG compared three rituximab protocols in terms of clinical status, relapse, changes in treatment, and adverse side effects. The primary effectiveness endpoint was clinical relapse requiring a further infusion of rituximab. Survival curves were estimated using Kaplan-Meier methods and survival analyses were undertaken using Cox proportional-hazards models. ResultsTwenty-five patients were included: 11 treated with protocol 4 + 2 (375 mg/m(2)/4 w…

0301 basic medicinemedicine.medical_specialtyTime to relapseRelapse rateGastroenterologyAssaigs clínics de medicaments03 medical and health sciencesMalalties del sistema nerviós0302 clinical medicineimmune system diseasesInternal medicineMedicineIn patientRelapse riskAdverse effectSurvival analysisbusiness.industryGeneral NeuroscienceNervous system DiseasesDrug testingmedicine.diseaseMyasthenia gravis030104 developmental biologyRituximabNeurology (clinical)business030217 neurology & neurosurgerymedicine.drug
researchProduct

Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycl…

2009

Background The prevalence of and risk factors for central nervous system recurrence in patients with acute promyelocytic leukemia are not well established and remain a controversial matter. Design and Methods Between 1996 and 2005, 739 patients with newly diagnosed acute promyelocytic leukemia enrolled in two consecutive trials (PETHEMA LPA96 and LPA99) received induction therapy-with all-trans retinoic acid and idarubicin. Consolidation therapy comprised three courses of anthracycline monochemotherapy (LPA96), with all-trans retinoic acid and reinforced doses of idarubicin in patients with an intermediate or high risk of relapse (LPA99). Central nervous system prophylaxis was not given. Re…

:Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons Cyclic::Hydrocarbons Aromatic::Polycyclic Hydrocarbons Aromatic::Naphthacenes::Anthracyclines::Daunorubicin::Idarubicin [Medical Subject Headings]:Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence [Medical Subject Headings]Male:Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]idarubicinGastroenterology:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Central Nervous System NeoplasmsLeukemia Promyelocytic AcuteRecurrenceRisk FactorsCumulative incidenceAntibiotics AntineoplasticHematologyMiddle Agedall-trans retinoic acidLeukemiamedicine.anatomical_structure:Named Groups::Persons::Age Groups::Adolescent [Medical Subject Headings]Femalemedicine.drugAcute promyelocytic leukemiaAdultcentral nervous system relapsemedicine.medical_specialty:Diseases::Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Myeloid::Leukemia Myeloid Acute [Medical Subject Headings]AnthracyclineAdolescentCentral nervous system:Check Tags::Male [Medical Subject Headings]TretinoinNeoplasias del sistema nervioso centralCentral nervous system diseaseTretinoinInternal medicine:Named Groups::Persons::Age Groups::Adult [Medical Subject Headings]medicineIdarubicinHumans:Named Groups::Persons::Age Groups::Adult::Aged [Medical Subject Headings]Letters to the Editor:Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons Acyclic::Alkenes::Polyenes::Carotenoids::Retinoids [Medical Subject Headings]Leucemia promielocítica agudaAgedAntibióticos antineoplásicosbusiness.industryprognostic factors:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antibiotics Antineoplastic [Medical Subject Headings]acute promyelocytic leukemiamedicine.diseaseSurgery:Diseases::Neoplasms::Neoplasms by Site::Nervous System Neoplasms::Central Nervous System Neoplasms [Medical Subject Headings]:Check Tags::Female [Medical Subject Headings]businessIdarubicin
researchProduct

ANALISI DI SICUREZZA DI SISTEMI DELL’IMPIANTO SPES

2014

Il progetto SPES prevede il bombardamento di un bersaglio in carburo di uranio con un fascio di protoni, in modo da generare, tramite reazione nucleare, specie radioattive all’interno del target. Le particelle radioattive generate vengono successivamente estratte, ionizzate, separate in massa ed accelerate come fascio di ioni radioattivo. Il presente lavoro di tesi ha riguardato lo studio di sicurezza di alcune unità dell'impianto SPES e si inserisce nell'ambito di una collaborazione di ricerca tra i Laboratori Nazionali di Legnaro ed il Dipartimento dell'Energia, sezione Nucleare, dell'Università degli Studi di Palermo. Tale attività ha comportato l'analisi sui componenti del sistema di pr…

ANALISI SICUREZZA RELAP5 EXCYTINFNSPESSettore ING-IND/19 - Impianti NucleariFMECA
researchProduct

Quantification of the risk of relapses after thyroid loboisthmusectomy for benign thyroid nodules

2006

AIM OF THE STUDY: To evaluate correlations between pre-operating epidemiological, clinical and diagnostic data and relapses concerning to patients operated on for benign thyroid nodules. MATERIAL AND METHODS: The AA. carried out a new ultrasonographic exam in 155 patients selected at random among 1012 treated by thyroid lobectomy between September 1976 and December 2002; 107 relapses were found (69%). The obtained data are analysed by chi2 test and a significant correlation between recurrence and data preceding first operation was found: non-homogeneous thyroid structure, multiple nodules, presence of peri-lesional halo, anti-thyroid antibodies, and non-adenomatous histological structure. C…

AdenomaAdultMaleChi-Square DistributionTime FactorsGoiterAge FactorsMiddle AgedGoitre relapse Thyroid lobectomyGraves DiseaseSex FactorsRecurrenceRisk FactorsThyroidectomyHumansFemaleThyroid NeoplasmsThyroid NoduleAgedFollow-Up StudiesGoiter NodularUltrasonography
researchProduct

Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis

2006

Cognitive dysfunction is considered one of the clinical markers of multiple sclerosis (MS). However, in the literature there are inconsistent reports on the prevalence of cognitive dysfunction, and separate data for the relapsing-remitting (RR) type of the disease are not always presented. In this study, we submitted 461 RRMS patients to a battery of neuropsychological tests to investigate their impairment in various cognitive domains. As a consequence of the exclusion criteria, the sample is not fully representative of the entire population of RRMS patients. In this selected sample, when only the eight scores of a core battery (Mental Deterioration Battery) were considered (with respectiv…

Adult050103 clinical psychologymedicine.medical_specialtyMultiple Sclerosismultiple sclerosis cognition single digit modality test information processingNeuropsychological TestsAudiologyDevelopmental psychology03 medical and health sciencesCognitionMultiple Sclerosis Relapsing-Remitting0302 clinical medicineMemoryOutpatientsOutpatients; Humans; Patient Selection; Multiple Sclerosis Relapsing-Remitting; Cognition; Cognition Disorders; Italy; Demography; Memory; Adult; Language; Neuropsychological Tests; SpeechmedicineHumansSpeech0501 psychology and cognitive sciencesMemory disorderCognitive deficitDemographyLanguagemedicine.diagnostic_testPatient SelectionMemoriaMultiple sclerosiscognition impairment05 social sciencesCognitive disorderNeuropsychologyCognitionNeuropsychological testmedicine.diseaserelapsing-remittingItalyinformation processing speedNeurologymultiple sclerosiSettore MED/26 - NeurologiaNeurology (clinical)medicine.symptomCognition DisordersPsychology030217 neurology & neurosurgeryrelapsing remitting
researchProduct